Research

A new AI model can accurately predict human response to novel drug compounds

The journey between identifying a potential therapeutic compound and Food and Drug Administration approval of a new drug can take well over a decade and cost upwards of a billion dollars. A research team at the CUNY Graduate Center has created an artificial intelligence model that could significantly improve the accuracy and reduce the time and cost of the drug development process.

Making pharmacy more sustainable

In the article published in the prestigious scientific journal Science, a group of international researchers, including Gorka Orive, Doctor of Pharmacy and researcher in the UPV/EHU's NanoBioCel group, and Unax Lertxundi of the Bioaraba Institute for Health Research, have issued a warning about the increase in pharmaceutical contamination.

Repurposing existing drugs to fight new COVID-19 variants

Michigan State University (MSU) researchers are using big data and AI to identify current drugs that could be applied to treat new COVID-19 variants.

Finding new ways to treat the novel coronavirus and its ever-changing variants has been a challenge for researchers, especially when the traditional drug development and discovery process can take years.

Similar medications cost more for humans compared to pets

In a research letter published in JAMA Internal Medicine, University of Minnesota researchers compared the prices of 120 medications commonly used in humans and pets. The authors found the price of human medications was generally higher than the price of pet medications with the same ingredients at common human-equivalent doses.

WHO strongly advises against antibody treatments for COVID-19 patients

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in The BMJ.

These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus's ability to infect cells.

Mucosal antibodies in the airways protect against omicron infection

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three doses of the SARS-CoV-2 vaccine. These are the findings of a study published today in The New England Journal of Medicine, led by researchers at Karolinska Institutet and Danderyd Hospital in Sweden.

Drug turns cancer gene into "eat me" flag for immune system

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now, UC San Francisco researchers have developed a drug that overcomes some of these barriers, marking cancer cells for destruction by the immune system.

Research & Development

A new AI model can accurately predict human response to novel drug compounds

Making pharmacy more sustainable

Repurposing existing drugs to fight new COVID-19 variants

Similar medications cost more for humans compared to pets

WHO strongly advises against antibody treatments for COVID-19 patients

Mucosal antibodies in the airways protect against omicron infection

Drug turns cancer gene into "eat me" flag for immune system

More Pharma News ...